Trial Profile
Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RPH-203 Following a Single Dose in Healthy Male Volunteers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs RPH 203 (Primary) ; RPH 203 (Primary)
- Indications Bone cancer
- Focus Adverse reactions; First in man
- 12 Mar 2016 Results of population modeling and simulation of Rph-203 effects presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 02 Jul 2013 New trial record